Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
WuXi Biologics said its MFG17 drug substance facility at the Shanghai Fengxian site has successfully completed its first GMP production campaign, with manufacturing executed without any deviations.
read more
WuXi Biologics has received FDA pre license inspection (PLI) approval for its MFG8 drug substance manufacturing facility in Hebei, clearing the way for commercial supply of a potential blockbuster autoimmune therapy.
read more
Thursday, February 28, 2019
WuXi Biologics congratulates its strategic partner Amicus Therapeutics on receiving FDA Breakthrough Therapy Designation for AT-GAA (ATB200/AT2221).
read more
Wednesday, December 02, 2020
WuXi Advanced Therapies announced the completion of a facility expansion that will triple its advanced testing capacity at the company's Philadelphia Navy Yard campus.
read more
Thursday, January 05, 2017
WuXi NextCODE, the contract genomics organization enabling precision medicine worldwide, and the National Heart Centre Singapore (NHCS), a leading national and regional cardiovascular medicine center, today announced their partnership to advance ...
read more
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, and Pacific Biomarkers (PBI), a premier biomarker laboratory services provider ...
read more
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical ...
read more
WuXi PharmaTech, a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, announced today that it has completed an expansion of its materials characterization testing facility in...
read more
WuXi PharmaTech has announced that its Laboratory Testing Division (LTD) has launched preclinical medical device testing services in China. These services are being offered for Chinese and international clients for their product registration with the...
read more
WuXi PharmaTech has announced that its toxicology facility in Suzhou recently passed a surveillance Good Laboratory Practice (GLP) inspection by FDA with no major observations.
read more
Wednesday, August 04, 2021
WuXi STA announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland from Bristol Myers Squibb. WuXi STA first announced its plans to purchase the facility earlier this year. The acquisition will ...
read more
WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO) has added two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing at its Changzhou campus.
read more
Thursday, December 01, 2022
WuXi STA, a subsidiary of WuXi AppTec announced the partnership with Multiply Labs (based in San Francisco, CA, USA), a robotics company that has developed industry-leading automated manufacturing systems to produce individualized drugs.
read more
Thursday, November 21, 2019
Under the terms of this agreement, WuXi STA will become the preferred Contract Development and Manufacturing Organization (CDMO) partner of Impact Therapeutics.
read more
STA Pharmaceutical announces that its API R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection for two APIs from the FDA – with no Form 483s issued.
read more